Transfusion-Transmitted Hepatitis A Virus, France, 2018
Caroline Lefeuvre, Caroline Lefort, Françoise Boyer, Sophie Le Cam, Lina Mouna, Anne‐Marie Roque‐Afonso, Hélène Le Guillou‐Guillemette, Rafaël Mahieu
Abstract
We report a transfusion-transmitted HAV infection that was identifi ed by postdonation information in addition to HAV RNA detection from additional quality control of plasma donations intended for use in manufacturing plasma-derived products. The index donation was collected from a male donor on August 28, 2018; after the donor interview and suitable routine screening, it was accepted for use. The donor interview did not reveal any relevant HAV risk factors (Figure Red blood cells, fresh frozen plasma, and pooled platelets (pathogen-inactivated by amotosalen and UV-A light) were manufactured from the donation. On September 2, 2018, the donor reported fever while his donated red blood cells and frozen plasma were still in inventory. The pooled platelets had been transfused to an immunocompromised male patient on August 31, 2018 (Figure Packed red blood cells were immediately destroyed in accordance with the blood bank's recommendation. The hemovigilance service promptly provided postdonation information to the prescribing physician. HAV RNA was identifi ed from the frozen plasma intended for fractionation on September 7, 2018. A frozen sample from a previous donation from this donor on June 23, 2018, was HAV RNA negative, as were samples from other platelet pool donors.